|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AB04
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:biosimilarName
|
gptkb:Cyltezo
gptkb:Amjevita
gptkb:Hadlima
gptkb:Hyrimoz
|
|
gptkbp:brand
|
gptkb:Humira
|
|
gptkbp:CASNumber
|
331731-18-1
|
|
gptkbp:contraindication
|
tuberculosis
active infection
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:AbbVie
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:halfLife
|
2 weeks
|
|
gptkbp:hasMolecularFormula
|
C6428H9912N1694O1987S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
adalimumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:KEGGID
|
D02597
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Abbott_Laboratories
gptkb:AbbVie
gptkb:Eisai
|
|
gptkbp:mechanismOfAction
|
TNF-alpha inhibitor
|
|
gptkbp:origin
|
fully human monoclonal antibody
|
|
gptkbp:patentExpired
|
2016 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:product
|
gptkb:IgG1_antibody
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201585
DB00051
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
nausea
headache
injection site reaction
rash
upper respiratory tract infection
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:UNII
|
FYS6T7F842
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
uveitis
ankylosing spondylitis
plaque psoriasis
hidradenitis suppurativa
|
|
gptkbp:bfsParent
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:bfsLayer
|
6
|